<DOC>
	<DOCNO>NCT00440440</DOCNO>
	<brief_summary>The purpose study find effect replace testosterone form gel ( AndrogelÂ® ) amount fat mass male low testosterone diabetes .</brief_summary>
	<brief_title>Effect Testosterone Gel Replacement Fat Mass Males With Low Testosterone Levels Diabetes</brief_title>
	<detailed_description>Hypogonadism associate increase fat mass , decrease muscle mass , accelerate bone loss , decrease libido effect mood . Androgen replacement context clearly beneficial , numerous study demonstrate improvement bone muscle mass , reduction body fat improvement insulin sensitivity , libido mood follow treatment . Testosterone replacement lead dose-dependent decrease adipose tissue increase muscle mass strength . The principal focus propose research evaluate effect androgel lean body mass regional adipose tissue mass ( include hepatic visceral fat ) type 2 diabetic patient hypogonadism , population likely benefit reduction adipose tissue increase muscle mass .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Males age 3575 year inclusive . Evidence hypogonadism : Hypogonadism define low total testosterone ( &lt; 300 ng/dL ) low calculate free testosterone ( 6.5ng/dL ; calculate use testosterone SHBG ) . Testosterone level measure 8 10 . Subjects normal total low free testosterone level ( vice versa ) ask come one week testosterone level remeasured . They include study free total testosterone level low remeasurement . Type 2 diabetes Hemoglobin A1c &lt; 8.0 % Subjects medication diabetes allow long stable dos compound least 6 week . The dose thiazolidinediones stable 3 month prior study . The dosage diabetic medication change study . Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous four week Hepatic disease ( transaminase &gt; 3 time normal ) Renal impairment ( serum creatinine &gt; 1.5 ) Chronic steroid therapy Use testosterone androgen ( DHEA ) last 3 month Panhypopituitarism HIV hepatitis C Subjects exclude study history prostate breast cancer , gonadal endocrine disorder Current recent history major psychiatric illness , significant uncontrolled systemic illness Sleep apnea History alcoholism substance abuse within past year History take drug might interfere result study ( ie , Lupron , finasteride , spironolactone , cimetidine , antiandrogens , estrogen , p450 enzyme inducer , barbiturate ) Abnormal prostate evidence prostatic symptom , prostatic mass induration rectal examination , elevated level prostate specific antigen ( &gt; 4 ng/mL ; subject PSA level 2.54 ng/mL permitted prostate biopsy negative ) positive biopsy , urine flow rate le 12 mL/s , International Prostate Symptom Score great 19 Hematocrit great 50 % Body weight &gt; 300 lb ( maximum weight accommodate DEXA MRI machine . The subject systolic blood pressure &gt; 170mmHg diastolic blood pressure &gt; 100 mmHg antihypertensive treatment . Generalized skin disease could affect absorption testosterone gel ( ie , psoriasis ) ; Morning prolactin level great 40 mg/mL Subjects serum fast triglyceride concentration &gt; 500 mg/dL screen history hypertriglyceridemiainduced pancreatitis . Participation concurrent clinical trial Any lifethreatening , noncardiac disease Use investigational agent therapeutic regimen within 30 day 5 halflives ( ever longer ) precede first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>hypogonadism</keyword>
	<keyword>diabetes</keyword>
	<keyword>visceral fat</keyword>
	<keyword>hepatic fat</keyword>
	<keyword>lean mass</keyword>
</DOC>